Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 21.04% is in line with its 5-year average of 20.13%, around the middle of its 5-year range (18.27%–24.04%).
3.59% above its 12-month average of 20.31%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
21.04%
EBITDA MARGIN AVG TTM
20.31%
EBITDA MARGIN AVG 3Y
20.33%
EBITDA MARGIN AVG 5Y
20.13%
EBITDA MARGIN AVG 10Y
19.24%
EBITDA MARGIN AVG 15Y
16.92%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+3.59%
CURRENT VS 3Y AVG
+3.50%
CURRENT VS 5Y AVG
+4.54%
CURRENT VS 10Y AVG
+9.35%
CURRENT VS 15Y AVG
+24.36%
CURRENT VS 20Y AVG
N/A
IQVIA Holdings Inc.
Market Cap
$43.08B
EBITDA Margin
21.04%
TTM Avg
20.31%
3Y Avg
20.33%
5Y Avg
20.13%
Market Cap
$42.96B
EBITDA Margin
18.31%
TTM Avg
11.44%
3Y Avg
6.73%
5Y Avg
5.67%
Market Cap
$41.67B
EBITDA Margin
25.43%
TTM Avg
26.12%
3Y Avg
26.05%
5Y Avg
25.37%
Market Cap
$41.22B
EBITDA Margin
34.08%
TTM Avg
33.18%
3Y Avg
32.37%
5Y Avg
31.82%
Market Cap
$49.58B
EBITDA Margin
23.08%
TTM Avg
23.14%
3Y Avg
23.23%
5Y Avg
22.53%
Market Cap
$50.08B
EBITDA Margin
29.55%
TTM Avg
28.88%
3Y Avg
30.96%
5Y Avg
31.73%
Market Cap
$35.17B
EBITDA Margin
15.00%
TTM Avg
4.83%
3Y Avg
-18.55%
5Y Avg
-52.26%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | $43.08B | 21.04% | 20.31% | 20.33% | 20.13% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.96B | 18.31% | 11.44% | 6.73% | 5.67% |
| Agilent Technologies, Inc. (A)vs › | $41.67B | 25.43% | 26.12% | 26.05% | 25.37% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $41.22B | 34.08% | 33.18% | 32.37% | 31.82% |
| Humana Inc. (HUM)vs › | $48.71B | 1.76% | 1.98% | 3.17% | 4.08% |
| Becton, Dickinson and Company (BDX)vs › | $49.58B | 23.08% | 23.14% | 23.23% | 22.53% |
| Edwards Lifesciences Corporation (EW)vs › | $50.08B | 29.55% | 28.88% | 30.96% | 31.73% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $35.17B | 15.00% | 4.83% | -18.55% | -52.26% |
| Alcon Inc. (ALC)vs › | $33.80B | 24.53% | 25.59% | 24.02% | 22.67% |
| ResMed Inc. (RMD)vs › | $32.19B | 36.98% | 37.16% | 34.64% | 34.36% |
Gross Margin
26.2%
EBITDA Margin
21.0%
Operating Margin
13.6%
Net Margin
8.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 18.27% |
| 2026-03-31 | 19.32% |
| 2025-12-31 | 24.04% |
| 2025-09-30 | 20.46% |
| 2025-06-30 | 19.47% |
| 2025-03-31 | 19.87% |
| 2024-12-31 | 23.47% |
| 2024-09-30 | 21.25% |
| 2024-06-30 | 21.42% |
| 2024-03-31 | 20.60% |
| 2023-12-31 | 21.12% |
| 2023-09-30 | 20.82% |
| 2023-06-30 | 21.00% |
| 2023-03-31 | 19.82% |
| 2022-12-31 | 19.68% |
| 2022-09-30 | 20.21% |
| 2022-06-30 | 20.78% |
| 2022-03-31 | 21.02% |
| 2021-12-31 | 20.08% |
| 2021-09-30 | 18.81% |
| 2021-06-30 | 18.36% |
| 2021-03-31 | 19.51% |
| 2020-12-31 | 19.19% |
| 2020-09-30 | 18.16% |
| 2020-06-30 | 15.41% |
| 2020-03-31 | 18.48% |
| 2019-12-31 | 16.58% |
| 2019-09-30 | 18.91% |
| 2019-06-30 | 17.92% |
| 2019-03-31 | 18.82% |
| 2018-12-31 | 18.64% |
| 2018-09-30 | 17.89% |
| 2018-06-30 | 17.61% |
| 2018-03-31 | 18.14% |
| 2017-12-31 | 18.67% |
| 2017-09-30 | 18.37% |
| 2017-06-30 | 16.82% |
| 2017-03-31 | 16.95% |
| 2016-12-31 | 14.31% |
| 2016-09-30 | 13.52% |
| 2016-06-30 | 11.77% |
| 2016-03-31 | 14.13% |
| 2015-12-31 | 13.96% |
| 2015-09-30 | 14.03% |
| 2015-06-30 | 13.05% |
| 2015-03-31 | 12.88% |
| 2014-12-31 | 13.52% |
| 2014-09-30 | 12.81% |
| 2014-06-30 | 12.74% |
| 2014-03-31 | 13.03% |
| 2013-12-31 | 11.42% |
| 2013-09-30 | 12.76% |
| 2013-06-30 | 9.25% |
| 2013-03-31 | 11.38% |
| 2012-12-31 | 9.39% |
| 2012-09-30 | 11.24% |
| 2012-06-30 | 10.12% |
| 2012-03-31 | 9.97% |
